If altered IDH1- enzyme activity or the novel enzymatic product 2-hydroxyglutarate [39] due to the mutation directly set the stage for an increased chromosomal and genetic instability of affected gliomas facilitating additional molecular events remains to be elucidated. This evidence concerns the gene IDH1 and central nervous system cancer.